New drug to prevent muscle loss and aid weight loss in older adults
Official title: Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults
Funded at Ridgeline Therapeutics, INC. · NIH-11419676 · Data updated 2026-11-12
A new adjunct medicine is being tested to prevent muscle loss and support weight loss in adults, especially older adults.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ridgeline Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Houston, UNITED STATES) |
| Project start | September 22, 2025 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $904,811 |
| NIH project number | 5R44AG092210-02 |
| Project ID | NIH-11419676 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults aged 60 and older who are dealing with obesity-related health issues and are considering weight-loss strategies.
✕Less likely to help
Adults without obesity-related conditions or without interest in weight-management strategies may not benefit.
What this research studies
This project explores a novel small molecule that may help older adults keep muscle while losing weight, potentially improving health and mobility. Researchers will preclinically validate the compound and its effect when combined with a low-fat diet in models that mimic human obesity and aging. The goal is to provide a safer, more effective option than current weight-loss therapies that often cause muscle loss or lose their effect over time. If results are positive, this could lead to future human studies and new treatment possibilities for obese or aging populations.
Why it matters
Potential benefit: If successful, the drug could help people lose weight while preserving muscle, potentially improving strength and daily functioning.
How similar studies have gone: Similar NNMT-targeting approaches in animal models showed weight and metabolic improvements, but human data are not yet established.
Where this research is happening
-
Ridgeline Therapeutics, INC.
Houston, United States Active
Researchers
- Principal investigator: Neelakantan, Harshini — Ridgeline Therapeutics, INC.
- Study coordinator: Neelakantan, Harshini
Related research
Other NIH-funded projects on the same topics.
-
Predicting Weight Regain After Weight Loss Through Body Signals
A study with people who are losing weight will check how their body’s metabolism and appetite signals might influence if they regain weight later.
-
Engaging men in weight loss with a game-based mental training and app program
A game-based mobile program designed for American men to help them lose weight by combining engaging gaming features with brain training.
-
Simplifying dietary self-monitoring to boost weight loss success
A study tests a lighter, easier way to track food to help adults with overweight or obesity lose weight through a digital program.
-
Activin signaling in muscles, aging, and weight loss
Aims to understand how activin signals in muscle affect aging, weight loss, and daily function, especially in older adults.
-
How the brain drives overeating and weight loss with GLP-1 medications
Scientists are studying how brain circuits that control food seeking respond to obesity and weight loss with a GLP-1 drug, to understand why weight loss often doesn’t hold.
-
Off-Ramp Feasibility: finding better ways to taper GLP-1 obesity medicines without weight regain
A small, patient-friendly trial tests how to taper off GLP-1 obesity medicines without quickly regaining weight.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.